You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Pexidartinib hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for pexidartinib hydrochloride and what is the scope of patent protection?

Pexidartinib hydrochloride is the generic ingredient in one branded drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pexidartinib hydrochloride has one hundred and thirty-five patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for pexidartinib hydrochloride
International Patents:135
US Patents:12
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 23
Clinical Trials: 17
Patent Applications: 28
What excipients (inactive ingredients) are in pexidartinib hydrochloride?pexidartinib hydrochloride excipients list
DailyMed Link:pexidartinib hydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pexidartinib hydrochloride
Generic Entry Date for pexidartinib hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for pexidartinib hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daiichi Sankyo Co., Ltd.Phase 2
Daiichi Sankyo, Inc.Phase 4
Daiichi Sankyo Co., Ltd.Phase 3

See all pexidartinib hydrochloride clinical trials

US Patents and Regulatory Information for pexidartinib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-002 Oct 14, 2022 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-002 Oct 14, 2022 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for pexidartinib hydrochloride

Country Patent Number Title Estimated Expiration
Taiwan 201907920 Formulations of a Compound modulating kinases ⤷  Sign Up
Japan 2015205880 C−FMSおよび/またはC−KIT活性を調節する化合物およびその用途 (COMPOUND FOR MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USE THEREFOR) ⤷  Sign Up
Nicaragua 200900093 COMPUESTOS QUE MODULAN LA ACTIVIDAD DE C-FMS Y/O C-KIT Y USO DE LOS MISMOS. ⤷  Sign Up
China 107531706 调节激酶的1H‑吡咯并[2,3‑b]吡啶衍生物的合成 (Synthesis of 1H-pyrrolo[2,3-b]pyridin derivatives modulating kinases) ⤷  Sign Up
Mexico 2017013975 FORMAS SOLIDAS DE QUINASAS QUE MODULAN UN COMPUESTO. (SOLID FORMS OF A COMPOUND MODULATING KINASES.) ⤷  Sign Up
Ukraine 97816 СПОЛУКИ, ЩО МОДУЛЮЮТЬ АКТИВНІСТЬ C-FMS І/АБО C-KIT, І ЇХ ЗАСТОСУВАННЯ[СОЕДИНЕНИЯ, КОТОРЫЕ МОДУЛИРУЮТ АКТИВНОСТЬ C-FMS И/ИЛИ C-KIT, И ИХ ПРИМЕНЕНИЕ (COMPOUNDS MODULATING C-KIT AND/OR C-FMS ACTIVITY AND USE THEREOF) ⤷  Sign Up
Japan 6530826 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.